HC Wainwright Has Positive Forecast for CADL Q2 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Research analysts at HC Wainwright upped their Q2 2026 earnings per share (EPS) estimates for shares of Candel Therapeutics in a note issued to investors on Friday, May 15th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.24) for the quarter, up from their prior forecast of ($0.27). The consensus estimate for Candel Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.85) EPS, FY2027 earnings at $0.35 EPS, FY2028 earnings at $0.71 EPS and FY2029 earnings at $1.45 EPS.

A number of other research firms also recently commented on CADL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Monday, April 20th. Zacks Research raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday. Cantor Fitzgerald assumed coverage on Candel Therapeutics in a report on Monday, April 20th. They set an “overweight” rating on the stock. Citigroup reduced their target price on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Finally, Wall Street Zen raised Candel Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Candel Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $18.00.

Candel Therapeutics Trading Down 9.9%

NASDAQ:CADL opened at $7.90 on Tuesday. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. The business’s 50 day moving average is $5.97 and its two-hundred day moving average is $5.64. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $9.27. The company has a market cap of $578.83 million, a PE ratio of -8.06 and a beta of -0.59.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.16.

Insider Activity

In related news, Director Paul B. Manning purchased 550,458 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the acquisition, the director owned 2,763,527 shares in the company, valued at approximately $15,061,222.15. This trade represents a 24.87% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 14.30% of the company’s stock.

Institutional Trading of Candel Therapeutics

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of Candel Therapeutics by 128.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $63,000. Bank of New York Mellon Corp boosted its stake in Candel Therapeutics by 43.1% during the 1st quarter. Bank of New York Mellon Corp now owns 136,266 shares of the company’s stock valued at $668,000 after purchasing an additional 41,058 shares during the period. Janus Henderson Group PLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $845,000. Finally, AlphaCentric Advisors LLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $178,000. Institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.